Application of cycloastragenol to preparation of drug for inhibiting abdominal aortic aneurysm

A technology for abdominal aortic aneurysm and abdominal aorta, which is applied in the application field of cycloastragenol in the preparation of drugs for inhibiting abdominal aortic aneurysm, achieving the effect of high yield, simple process and strong pharmacological effect

Active Publication Date: 2018-09-07
PEKING UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are currently no reports on the

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cycloastragenol to preparation of drug for inhibiting abdominal aortic aneurysm
  • Application of cycloastragenol to preparation of drug for inhibiting abdominal aortic aneurysm
  • Application of cycloastragenol to preparation of drug for inhibiting abdominal aortic aneurysm

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0087] Embodiment 1, the application of cycloastragenol in the prevention of abdominal aortic aneurysm

[0088] 1. Mouse infrarenal aorta incubated with elastase to induce abdominal aortic aneurysm model

[0089] Experimental animals: 10-week-old male C57BL / 6J mice (average body weight 23 g).

[0090] The experimental animals were divided into model group and sham operation group (12 in the model group and 3 in the sham operation group).

[0091] 1. Experimental animals were anesthetized by intraperitoneal injection of 5% chloral hydrate (injection according to body weight, 8 μL / g).

[0092] 2. After completing the anesthesia in step 1, the infrarenal abdominal aorta was separated, and a section of the abdominal aorta (about 1 cm in length) with no branches on the anterior wall and side wall was taken below the plane of the renal artery, and fixed with threading marks. In the model group, gauze soaked with 2U elastase was wrapped around the exposed abdominal aorta. After 50 ...

Embodiment 2

[0098] Example 2. Intragastric administration of cycloastragenol to treat abdominal aortic aneurysm induced by infrarenal artery of C57BL / 6J mice incubated with elastase

[0099] 1. Mouse infrarenal aorta incubated with elastase to induce abdominal aortic aneurysm model

[0100] Same as Step 1 of Example 1.

[0101] 2. Oral administration of cycloastragenol

[0102] 1. After 14 days of completing step 1, the mice in the model group were randomly divided into a normal saline group and a cycloastragenol group (6 mice in each group), and the cycloastragenol group mice were intragastrically administered with cycloastragenol every day (cycloastragelol dissolved In 0.01M PBS solution, the intragastric administration dose is 125mg cycloastragenol / kg body weight), the mice in the normal saline group were intragastrically administered with normal saline (200 μL / only), and the mice in the sham operation group were intragastrically administered with normal saline (200 μL / only). / piece)...

Embodiment 3

[0106] Example 3, cycloastragenol inhibits the injury of rat vascular smooth muscle cells induced by TNF-α

[0107] 1. Preparation of rat vascular smooth muscle cells

[0108] SD rats (body weight about 100 g) were anesthetized with 10% chloral hydrate, soaked in 75% alcohol for 2 min for disinfection. The chest cavity and abdominal cavity were opened, the organs were pushed aside, the heart and aorta were exposed, and the blood was sucked away with gauze. Carefully cut the full length of the heart and aorta up to the bifurcation of the abdominal aorta, and immediately put it in 0.01M PBS buffer. The adipose tissue and connective tissue were separated, and the heart was carefully cut off, during which the heart was washed three times with 0.01M PBS buffer. The separated transparent aorta was washed once in DMEM containing 0.05g / 100ml amphotericin B. The aorta was then cut longitudinally, the intima was scraped off, and the aorta was minced. Transfer the cut aortic tissue p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of cycloastragenol to preparation of a drug for inhibiting abdominal aortic aneurysm. The invention provides application of cycloastragenol to preparation of products for preventing and/or treating abdominal aortic aneurysm, and/or to prevention and/or treatment abdominal aortic aneurysm. The invention also provides a drug for preventing and/or treating abdominal aortic aneurysm. The active component of the drug is cycloastragenol. The drug for inhibiting abdominal aortic aneurysm is safe and has low toxicity and strong pharmacological action; the raw material of the drug is widely available and low in price, and can be prepared through hydrolysis of the astragalus extract astragaloside; a preparation method for the drug is low in cost, simple in processand high in yield; and the curative effect of the drug is definite. According to the invention, a novel drug source is provided for preventing, diagnosing, detecting, protecting, treating and researching abdominal aortic aneurysm diseases, and is easy to promote and apply and capable of generating enormous social and economic benefits in a short period of time.

Description

technical field [0001] The invention relates to the application of cycloastragenol in the preparation of medicine for inhibiting abdominal aortic aneurysm. Background technique [0002] Abdominal aortic aneurysm (AAA) is a severe progressive degenerative disease characterized by dilation of the abdominal aorta, accompanied by degradation of the extracellular matrix of the arterial wall and the occurrence of chronic inflammation. The incidence rate of AAA among elderly men over 65 years old is as high as 8%, and the incidence rate of AAA is slightly higher than that of women. It is the 13th cause of death in our country. Smoking, advanced age and atherosclerosis have been proven to be the most important risk factors for AAA. Most AAA patients have no obvious clinical symptoms except occasional abdominal pain, and a small number of patients have ruptured tumors when they are discovered. The mortality rate after rupture is as high as 80%, which is a serious hazard to human hea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/58A61P35/00A61P9/00A61P39/00A61P43/00
CPCA61K31/58
Inventor 祁荣王云霞
Owner PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap